Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Ginkgo Bioworks Holdings insider Steven P. Coen reported routine equity compensation activity involving restricted stock units and a related tax sale. On May 21, 2026, he exercised awards covering a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.
On May 22, 2026, 307 shares of Class A Common Stock were sold at $8.334 per share to cover tax withholding obligations tied to the vesting of restricted stock and/or RSUs, as allowed under the company’s equity incentive plans. The footnotes state these "sell to cover" sales are not discretionary trades by the reporting person. After these transactions, Coen directly held 50,704 shares of Class A Common Stock.
The filing reports a proposed sale of 307 Class A shares tied to a Restricted Stock Vesting event with an issuer designation and a trade date of 05/21/2026. The excerpt also lists prior dispositions by Steve Coen: 708 shares on 03/16/2026, 33,171 shares on 04/13/2026, and 324 shares on 04/17/2026.
Ginkgo Bioworks Holdings, Inc. ownership disclosure: Viking Global Investors and affiliated entities report shared beneficial ownership of 3,577,128 shares of Class A Common Stock. The filing amends prior reports to remove David C. Ott as a reporting person effective March 31, 2026.
The filing states those 3,577,128 shares represent 7.1% of Class A Common Stock based on 50,254,065 shares outstanding as of March 31, 2026. The stake includes 2,900,025 directly held shares and 677,103 shares subject to forfeiture if price targets are not met.
Austin Che submitted a Form 144 reporting proposed sales of Class A shares. The notice lists 2,200 Class A shares tied to a Restricted Stock Vesting dated 10/20/2022. The filing also records securities sold during the past three months: 2,200 shares on 03/11/2026, 40,893 shares on 04/13/2026 (showing $262,291.79), and 2,200 shares on 04/15/2026. The broker identified is Fidelity Brokerage Services LLC.
Ginkgo Bioworks Holdings, Inc. reported another quarterly loss while executing a major portfolio shift in early 2026. For the three months ended March 31, 2026, revenue from continuing operations was $19.5 million, with a net loss from continuing operations of $76.1 million and total net loss of $82.6 million.
The company completed a strategic divestiture of its Biosecurity business: in April 2026 it transferred substantially all Biosecurity operations to Perimeter Systems in exchange for an equity stake representing about 20% of the purchaser on a fully diluted basis. Biosecurity results are now reported as discontinued operations, contributing a further $6.5 million loss in the quarter.
As of March 31, 2026, Ginkgo held $143.9 million in cash and cash equivalents and $229.6 million in marketable securities, with total assets of $1.03 billion and stockholders’ equity of $443.2 million. Operating activities used $46.7 million of cash in the quarter, and a previously unrestricted $47.0 million of cash became restricted in April 2026 to secure a surety bond tied to an automation equipment contract.
Ginkgo Bioworks Holdings, Inc. reported first quarter 2026 results and highlighted its post-divestiture focus on autonomous labs. Revenue was $19.5 million, down 49% from the prior year quarter, largely due to program rationalization and the absence of prior non-cash deferred revenue releases.
The company posted a GAAP net loss from continuing operations of $76.1 million, modestly improved from $83.3 million a year earlier, and an Adjusted EBITDA loss of $42.3 million compared with $44.2 million. Cash, cash equivalents and marketable securities totaled $373 million as of March 31, 2026.
Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, which is now reported as discontinued operations. Management emphasized scaling its Nebula autonomous lab, growth in its Cloud Lab, Datapoints and Solutions offerings, and reaffirmed expected full-year 2026 total cash burn of $(150)–$(125) million.
Ginkgo Bioworks Holdings, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 8:00 a.m. Eastern Time. Shareholders will elect six directors, ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and cast an advisory vote on executive compensation, with the Board recommending “FOR” each item.
Holders of Class A common stock have one vote per share and holders of Class B common stock have ten votes per share, with 53,172,097 Class A shares and 8,963,350 Class B shares outstanding as of April 15, 2026. The proxy describes Ginkgo’s dual‑class governance, board committee structure, director pay (cash retainers plus stock options), and a pay program that emphasizes equity, including performance‑based restricted stock units for executives.
The filing also notes Deloitte audit fees of $4,042,215 for 2025 and summarizes the 2024 transition from EY to Deloitte, including previously reported material weaknesses in internal control over financial reporting. Shareholders may vote online, by phone, by mail, or during the virtual meeting.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported routine equity compensation activity involving restricted stock units. On April 16, 2026, he exercised RSUs to acquire a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, reflecting vesting of previously granted awards.
On April 17, 2026, Coen sold 324 shares of Class A Common Stock at an average price of $7.952 per share. According to the disclosure, these shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and RSUs and are not considered discretionary trades. After these transactions, he directly holds 50,268 shares of Class A Common Stock.
DNA filed a Form 144 reporting proposed sales of Class A shares. The notice lists a proposed sale of 324 Class A shares tied to restricted stock vesting dated 04/16/2026. It also discloses recent reported sales by Steve Coen: 972 shares on 01/20/2026, 708 shares on 03/16/2026, and 33,171 shares on 04/13/2026, each with the corresponding proceeds shown in the filing.